Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


News In Brief

This article was originally published in The Gray Sheet

Executive Summary

President issues business tax reform plan, patent battles heat up in fetal lab test space, and more news.

You may also be interested in...

Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies

The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.

Democratic National Platform Advances President’s Corporate Tax Reform Proposals

Permanent R&D tax credit, reduced corporate tax rates and a minimum tax on foreign earnings are included in the Democratic platform adopted last week at the party’s convention in Charlotte, N.C.

House Device Tax Repeal Effort May Raise Profile Of Issue In Election Season

Legislation to repeal the impending medical device excise tax will be sent to a vote on the House floor, raising the profile of the tax as a congressional election issue even as major impediments to repeal remain in the Senate. Meanwhile, the Supreme Court health care reform ruling looms.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts